COVID-19 Funding and Funding Opportunities from the National Institutes of Health
NIH is devoting significant resources to COVID-19 by issuing new NOSIs (Notices of Special Interest). Check back for these and other COVID-19-related information on the NIH Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding website.
In addition to dedicating regularly appropriated funds, to date NIH has received emergency funding for COVID-19-related activities that together provide additional opportunities for the following institutes/centers:
- $1.532 billion for NIAID
- $103.4 million for NHLBI
- $60 million for NIBIB
- $36 million for NCATS
- $30 million for the NIH Office of Director
- $10 million for NIEHS
- $10 million for NLM
To get funding as quickly as possible to the research community, NIH is using Urgent and Emergency competing revisions and administrative supplements to existing grant awards, allowing NIH to fund applications quickly, often in under three months, sometimes much quicker than that, because evaluation for scientific and technical merit is done by an internal review panel convened by staff of the NIH awarding institute or center rather than by the traditional peer review process.
The Urgent and Emergency competing revision FOAs sound similar but are distinct:
- The Emergency Competitive Revision FOA can only be used by those NIH Institutes and Centers listed above that received special emergency funding.
- The Urgent Competitive Revision FOA can be used to meet immediate needs to help address a specific public health crisis in a timely manner. This vehicle is used to help address a specific public health crisis that was unforeseen when the application or progress report was submitted.
These applications must be submitted in response to an Emergency or Urgent NOSI.
